

EXKIVITY (mobocertinib)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Exkivity (mobocertinib) is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that covalently binds to and inhibits EGFR exon 20 insertion mutations. EGFR is a protein involved in the growth and spread of cancer cells that is detected in many human cancers, including lung cancer. In animal models, Exkivity demonstrated anti-tumor activity against xenografts with the EGFR exon 20 insertions (1).

Regulatory Status

FDA-approved indication: Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test whose disease has progressed on or after platinum-based chemotherapy (1).

Exkivity has a boxed warning regarding QT (QTc) prolongation and the possibility of Torsades de Pointes, a potentially fatal heart arrhythmia. Patients should be monitored for QT prolongation, electrolytes at baseline and periodically during treatment. Concomitant administration with drugs that are known to prolong the QTc interval and strong or moderate CYP3A inhibitors should be avoided. If QT prolongation occurs, the dose of Exkivity should be reduced or permanently discontinued depending upon the severity of prolongation (1).

Exkivity has warnings regarding the following: interstitial lung disease (ILD)/pneumonitis, cardiac toxicity, diarrhea, and embryo-fetal toxicity (1).

Exkivity can cause fetal harm when administered in pregnant women. Pregnancy status in females of reproductive potential should be verified prior to initiating Exkivity. Females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 1 month after the last dose of Exkivity. Males with female partners of reproductive potential should be advised to use effective contraception during treatment with Exkivity and for 1 week after the last dose (1).

The safety and effectiveness of Exkivity in pediatric patients have not been established (1).

EXKIVITY (mobocertinib)

Summary

Exkivity (mobocertinib) is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that covalently binds to and inhibits EGFR exon 20 insertion mutations. It is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. Exkivity has a boxed warning regarding QTc prolongation, and patients should be monitored for QTc prolongation and its risk factors at baseline and periodically during treatment. Exkivity has warnings regarding the following: interstitial lung disease (ILD)/pneumonitis, cardiac toxicity, diarrhea, and embryo-fetal toxicity. The safety and effectiveness of Exkivity in pediatric patients have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Exkivity while maintaining optimal therapeutic outcomes.

References

1. Exkivity [package insert]. Lexington, MA: Takeda Pharmaceutical America, Inc.; September 2023.
2. NCCN Drugs & Biologics Compendium® Mobocertinib 2025. National Comprehensive Cancer Network, Inc. Accessed on January 15, 2025.